Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)

NCT02126579 is registered in ClinicalTrials.gov with Craig L Slingluff, Jr as lead sponsor.

NCT NCT02126579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02126579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Lead sponsor
Craig L Slingluff, Jr
Phase
Phase 1/2
Overall status
Completed
Start date
May 1, 2014
Completion date
May 5, 2021
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, metastatic melanoma, mucosal melanoma